REG - Sopheon PLC IOps Buyer Inc. - Publication of Scheme Document

SopheonAnnouncement

16/01/2024 17:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240116:nRSP9042Za&default-theme=true

RNS Number : 9042Z  Sopheon PLC  16 January 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

FOR IMMEDIATE RELEASE

 
 
                               16 January 2024

 

RECOMMENDED CASH OFFER

by

IOPS BUYER INC.

(a wholly-owned subsidiary of Wellspring Worldwide Inc.)

 

for

 

SOPHEON PLC

Publication of Scheme Document

On 22 December 2023, the boards of Sopheon Plc ("Sopheon") and IOps Buyer Inc.
("Bidco"), a wholly-owned subsidiary of Wellspring Worldwide Inc.
("Wellspring"), which is a portfolio company of funds managed and/or advised
by Resurgens, announced that they had reached agreement on the terms of a
recommended all cash offer pursuant to which Bidco would acquire the entire
issued and to be issued share capital of Sopheon (the "Acquisition"). It is
intended that the Acquisition will be effected by means of a Court-sanctioned
scheme of arrangement of Sopheon under Part 26 of the Companies Act 2006 (the
"Scheme").

Publication of the Scheme Document

Sopheon is pleased to announce that it has today published a circular in
relation to the Scheme ("Scheme Document"), setting out, amongst other things,
a letter from the Chair of Sopheon, an explanatory statement pursuant to
section 897 of the Companies Act 2006, the full terms and conditions of the
Scheme, an expected timetable of principal events, notices of the Court
Meeting and General Meeting (together, the "Meetings") and confirmation that
details of the action to be taken by Sopheon Shareholders will be published on
Sopheon's website at https://www.sopheon.com/investors
(https://www.sopheon.com/investors) . The Forms of Proxy were also published
today.

Hard copies of the Scheme Document and the Forms of Proxy for the Meetings are
being posted today to Sopheon Shareholders and, for information only, to
persons with information rights. Sopheon will also be sending details of the
proposals to be made to Sopheon Share Plan Participants.

Capitalised terms used in this announcement shall, unless otherwise defined,
have the same meanings as set out in the Scheme Document. All references in
this Announcement to times are to London, United Kingdom time unless otherwise
stated.

Recommendation

The Sopheon Directors, who have been so advised by Cavendish as to the
financial terms of the Acquisition, consider the terms of the Acquisition to
be fair and reasonable. In providing its advice to the Sopheon Directors,
Cavendish has taken into account the commercial assessments of the Sopheon
Directors. Cavendish is providing independent financial advice to the Sopheon
Directors for the purposes of Rule 3 of the Takeover Code.

Accordingly, the Sopheon Directors recommend unanimously that Sopheon
Shareholders vote in favour of the Scheme at the Court Meeting and in favour
of the Special Resolution at the General Meeting, as the Sopheon Directors
have irrevocably undertaken to do in respect of their own (and their connected
persons') entire beneficial holdings of Sopheon Shares (held in a personal
capacity or through a nominee), amounting to 2,340,668 Sopheon Shares,
representing, in aggregate, approximately 21.86 per cent. of the issued share
capital of Sopheon as at the Last Practicable Date.

In addition to the irrevocable undertakings from the Sopheon Directors, Bidco
has also received an irrevocable undertaking to vote or procure votes in
favour of the Scheme at the Court Meeting and in favour of the Special
Resolution at the General Meeting (or, if Bidco exercises its right to
implement the Acquisition by way of a Takeover Offer, to accept such offer)
from Rivomore Limited, in respect of 2,074,308 Sopheon Shares (held in a
personal capacity or through a nominee) representing, in aggregate,
approximately 19.37 per cent.  of the issued share capital of Sopheon as at
the Last Practicable Date. In aggregate, Bidco has received irrevocable
undertakings to vote in favour of the Scheme at the Court Meeting and in
favour of the Special Resolution at the General Meeting from the holders of
4,414,976 Sopheon Shares in total representing approximately 41.24 per cent.
of Sopheon's issued share capital as at the Last Practicable Date.

Actions required and notices of the Court Meeting and General Meeting

As detailed further in the Scheme Document, to become Effective, the Scheme
requires, among other things, the approval of a majority in number of Scheme
Shareholders present and voting (and entitled to vote), either in person or by
proxy at the Court Meeting, representing not less than 75 per cent. in nominal
value of the Scheme Shares held by such Scheme Shareholders present and voting
at the Court Meeting (or any adjournment of the Court Meeting) and the passing
of the Special Resolution necessary to implement the Scheme at the General
Meeting. Following the Court Meeting and the General Meeting and the
satisfaction (or, where applicable, waiver) of the other Conditions, the
Scheme must also be sanctioned by the Court. The Scheme will only become
Effective upon a copy of the Court Order being delivered to the Registrar of
Companies. Upon the Scheme becoming Effective, it will be binding on all
Scheme Shareholders, irrespective of whether or not they attended and/or voted
at the Meetings (and, if they attended and/or voted, whether or not they voted
in favour).

It is important that, for the Court Meeting in particular, as many votes as
possible are cast so that the Court may be satisfied that there is a fair and
reasonable representation of Scheme Shareholders' opinion. Scheme Shareholders
are therefore strongly urged to complete, sign and return their Forms of Proxy
or appoint a proxy through CREST or electronically (as appropriate) as soon as
possible.

Notices of the Meetings, each of which will be held at to be held at the
offices of Squire Patton Boggs (UK) LLP, 60 London Wall, London, EC2M 5TQ on
Thursday 8 February 2024, are set out in the Scheme Document. The Court
Meeting will start at 10:00 a.m. on that date and the General Meeting will
start at 10:15 a.m. on that date (or as soon as reasonably practicable
thereafter as the Court Meeting shall have been concluded or adjourned).

Timetable

The Scheme Document contains an expected timetable of principal events in
relation to the Scheme, which is also set out in the Appendix to this
Announcement.

Subject to obtaining the approval of the requisite majority of Scheme
Shareholders at the Court Meeting, the requisite majority
of Sopheon Shareholders at the General Meeting, the satisfaction or, as the
case may be, waiver of the Conditions, it is currently expected that the
effective date ("Effective Date") will be  20 February 2024.

All dates and times are based on Sopheon's, Resurgens', Wellspring's and
Bidco's current expectations and are subject to change. If any of the dates
and/or times in this expected timetable change, the revised dates and/or times
will be notified to Sopheon Shareholders by announcement through a Regulatory
Information Service and by posting notice of these dates on the following
website: https://www.sopheon.com/investors.

Cancellation of admission to trading

If the Scheme is sanctioned as outlined above, the last day of dealings in,
and for registration of transfers of, Sopheon Shares is expected to be 19
February 2024 (being the Business Day immediately before the Effective Date),
following which Sopheon Shares will be suspended from trading on AIM with
effect from 7:30 a.m. on the Effective Date.

Sopheon intends that, prior to the Scheme becoming Effective, an application
will be made to the London Stock Exchange for the cancellation of the
admission to trading of the Sopheon Shares on AIM with effect from shortly
after the Effective Date.

Additional Information

If you have any questions about this document, the Meetings, how to complete
the Forms of Proxy or how to appoint a proxy through the CREST electronic
proxy appointment service or otherwise, please contact Link Group on +44
(0)371 664 0321. Calls are charged at the standard geographic rate and will
vary by provider. Calls outside the United Kingdom will be charged at the
applicable international rate. Different charges may apply to calls from
mobile telephones and calls may be recorded and randomly monitored for
security and training purposes. Lines are open between 9:00 a.m. to 5:30 p.m.,
Monday to Friday excluding public holidays in England and Wales. The helpline
cannot provide advice on the merits of the Acquisition nor give any financial,
legal or tax advice.

Enquiries:

 

 Sopheon                                                               via Cavendish
 Andy Michuda, Executive Chairman
 Greg Coticchia, Chief Executive Officer
 Arif Karimjee, Chief Financial Officer

 Cavendish (Nominated Adviser and Broker to the Company)               +44 (0) 20 7220 0500
 Henrik Persson
 Carl Holmes

 Abigail Kelly
 George Dollemore

 Resurgens, Wellspring and Bidco                                       via Raymond James
 Adi Filipovic
 Fred Sturgis
 Danny Carpenter

 Raymond James (Financial Adviser to Resurgens, Wellspring and Bidco)  +44 (0) 20 3798 5700
 Junya Iwamoto
 Felix Beck

 

King & Spalding International LLP are retained as legal advisers to
Resurgens, Wellspring and Bidco.

 

Squire Patton Boggs (UK) LLP are retained as legal adviser to Sopheon.

 

Important Notices

 

Cavendish, which is authorised and regulated in the United Kingdom by the FCA,
is acting as financial adviser to Sopheon and no one else in connection with
the matters described in this Announcement and will not be responsible to
anyone other than Sopheon for providing the protections offered to clients of
Cavendish or for providing advice in connection with any matter referred to in
this Announcement. Neither Cavendish nor any of its affiliates (nor their
respective directors, officers, employees or agents) owes or accepts any duty,
liability or responsibility whatsoever (whether direct or indirect, whether in
contract, in tort, under statute or otherwise) to any person who is not a
client of Cavendish in connection with this Announcement, any statement
contained herein, the Scheme or otherwise. No representation or warranty,
express or implied, is made by Cavendish as to the contents of this
Announcement.

 

Raymond James, which is authorised and regulated in the United Kingdom by the
FCA, is acting as financial adviser to Resurgens, Wellspring and Bidco and
no-one else in connection with the matters described in this Announcement and
will not be responsible to anyone other than Resurgens, Wellspring or Bidco
for providing the protections afforded to clients of Raymond James nor for
providing advice in connection with the matters referred to herein. Neither
Raymond James nor any of its affiliates owes or accepts any duty, liability or
responsibility whatsoever (whether direct or indirect, whether in contract, in
tort, under statute or otherwise) to any person who is not a client of Raymond
James in connection with this Announcement, any statement contained herein,
the Acquisition or otherwise.

 

Further Information

 

This Announcement is for information purposes only and is not intended to and
does not constitute, or form any part of, an offer to sell or subscribe for or
any invitation to purchase or subscribe for any securities or the solicitation
of any vote or approval in any jurisdiction pursuant to the Acquisition or
otherwise. The Acquisition will be made solely through and on the terms set
out in the Scheme Document (or, in the event that the Acquisition is to be
implemented by means of a Takeover Offer, the offer document) and the
accompanying Forms of Proxy, which will contain the full terms and conditions
of the Acquisition, including details of how to vote in respect of the
Acquisition. Any approval, decision or other response to the Acquisition
should be made only on the basis of the information in the Scheme Document.
Scheme Shareholders are strongly advised to read the formal documentation in
relation to the Acquisition once it has been despatched.

 

The statements contained in this Announcement are made as at the date of this
Announcement, unless some other time is specified in relation to them, and
service of this Announcement shall not give rise to any implication that there
has been no change in the facts set forth in this Announcement since such
date.

 

Overseas Shareholders

 

This Announcement has been prepared for the purpose of complying with English
law, the AIM Rules and the Code and the information disclosed may not be the
same as that which would have been disclosed if this Announcement had been
prepared in accordance with the laws of jurisdictions outside the United
Kingdom.

 

The laws of the relevant jurisdictions may affect the availability of the
Acquisition to persons who are not resident in the United Kingdom. Persons who
are not resident in the United Kingdom, or who are subject to laws of any
jurisdiction other than the United Kingdom, should inform themselves about,
and observe any applicable requirements. Any person (including, without
limitation, nominees, trustees and custodians) who would, or otherwise intends
to, forward this Announcement, the Scheme Document or any accompanying
document to any jurisdiction outside the United Kingdom should refrain from
doing so and seek appropriate professional advice before taking any action. In
particular, the ability of persons who are not resident in the United Kingdom
to vote their Sopheon Shares at the Court Meeting or the General Meeting, or
to execute and deliver Forms of Proxy appointing another to vote their Sopheon
Shares in respect of the Court Meeting or the General Meeting on their behalf,
may be affected by the laws of the relevant jurisdiction in which they are
located.

 

Any failure to comply with the applicable legal or regulatory requirements may
constitute a violation of the laws and/or regulations of any such
jurisdiction. To the fullest extent permitted by applicable law, the companies
and persons involved in the Acquisition disclaim any responsibility and
liability for the violation of such restrictions by any person.

 

The Acquisition will not be made, directly or indirectly, in or into or by use
of the mails or any other means or instrumentality (including, without
limitation, telephonic or electronic) of interstate or foreign commerce of, or
any facility of a national, state or other securities exchange of, a
Restricted Jurisdiction, and the Acquisition will not be capable of acceptance
by any such use, means, instrumentality or facility or from within a
Restricted Jurisdiction. Accordingly, copies of this Announcement and formal
documentation relating to the Acquisition are not being, and must not be,
directly or indirectly, mailed or otherwise forwarded or distributed in, into
or from a Restricted Jurisdiction and persons receiving this Announcement
(including custodians, nominees and trustees) must not distribute or send it
into or from a Restricted Jurisdiction. In the event that the Acquisition is
implemented by way of a Takeover Offer and extended into the US, Bidco will do
so in satisfaction of the procedural and filing requirements of US securities
laws at that time, to the extent applicable thereto. The Acquisition relates
to the shares of a company incorporated in England and it is proposed to be
made by means of a scheme of arrangement provided for under English law. The
Scheme will relate to the shares of a UK company that is a "foreign private
issuer" as defined under Rule 3b-4 under the US Exchange Act. A transaction
effected by means of a scheme of arrangement is not subject to any shareholder
vote, proxy solicitation and tender offer rules under the US Exchange Act.

 

Accordingly, the Scheme is subject to the disclosure requirements and
practices applicable in the UK to schemes of arrangement, which differ from
the disclosure requirements and practices of US shareholder vote, proxy
solicitation or tender offer rules. Financial information included in the
relevant documentation will have been prepared in accordance with accounting
standards applicable in the UK and may not be comparable to the financial
information of, or the accounting standards applicable to, US companies.
However, if Bidco were to elect to implement the Acquisition by means of a
Takeover Offer, such Takeover Offer shall be made in compliance with all
applicable laws and regulations, including section 14(e) of the US Exchange
Act and Regulation 14E thereunder, if applicable. Such Takeover Offer would be
made in the US by Bidco and no one else. In addition to any such Takeover
Offer, Bidco, certain affiliated companies and the nominees or brokers (acting
as agents) may make certain purchases of, or arrangements to purchase, shares
in Sopheon outside such Takeover Offer during the period in which such
Takeover Offer would remain open for acceptance. If such purchases or
arrangements to purchase are made they would be made outside the United States
in compliance with applicable law, including the US Exchange Act. It may be
difficult for a US-based investor to enforce his or her rights and any claim
he or she may have arising under US securities laws, since the Scheme relates
to the shares of a company located in the UK, and some or all of its officers
and directors may be residents of non-US jurisdictions. A US-based investor
may not be able to sue a company located in the UK, or its officers or
directors, in a foreign court for alleged violations of US securities laws,
and it may be difficult to compel a foreign company and its affiliates to
subject themselves to a US court's judgment.

 

Forward-looking statements

 

This Announcement, oral statements made regarding the Acquisition, and other
information published by Sopheon, Bidco, Wellspring and Resurgens may contain
certain "forward-looking statements" with respect to Sopheon, Bidco,
Wellspring and Resurgens. These forward-looking statements can be identified
by the fact that they do not relate only to historical or current facts.
Forward-looking statements often use words such as "anticipate", "target",
"expect", "estimate", "intend", "plan", "goal", "believe", "will", "may",
"should", "would", "could" or other words or terms of similar meaning or the
negative thereof. Forward-looking statements include statements relating to,
for example, the following: (i) future capital expenditures, expenses,
revenues, earnings, synergies, economic performance, indebtedness, financial
condition, dividend policy, losses and future prospects; (ii) business and
management strategies of Resurgens, Wellspring and/or Bidco and the expansion
and growth of Sopheon and potential synergies resulting from the Acquisition;
and (iii) the effects of government regulation on the business of Sopheon.

 

These forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results, performance or
developments to differ materially from those expressed in or implied by such
forward-looking statements. These forward-looking statements are based on
numerous assumptions regarding present and future strategies and environments.
None of Resurgens, Wellspring, Bidco or Sopheon, nor any of their respective
associates, directors, officers, employees or advisers, provides any
representation, assurance or guarantee that the occurrence of the events
expressed or implied in any forward-looking statements in this Announcement
will actually occur. You are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date hereof. All
subsequent oral or written forward-looking statements attributable to
Resurgens, Wellspring, Bidco or Sopheon or any person acting on their behalf
are expressly qualified in their entirety by the cautionary statement above.
Should one or more of these risks or uncertainties materialise, or should
underlying assumptions prove incorrect, actual results may vary materially
from those described in this Announcement. None of Resurgens, Wellspring,
Bidco or Sopheon assume any obligation to update publicly or revise
forward-looking or other statements contained in this Announcement, whether as
a result of new information, future events or otherwise, except to the extent
legally required.

 

Publication on website

 

In accordance with Rule 26.1 of the Code, a copy of this Announcement will be
made available (subject to certain restrictions relating to persons resident
in Restricted Jurisdictions), free of charge, on Sopheon's website at
www.sopheon.com/investors and on Bidco's website at
https://offer.wellspring.com/news by no later than 12:00 noon on the Business
Day following this Announcement. Neither the contents of this website nor the
content of any other website accessible from hyperlinks on such websites is
incorporated into, or forms part of, this Announcement.

 

Requesting hard copies

 

In accordance with Rule 30.3 of the Code, a person so entitled may request a
hard copy of this Announcement, free of charge, by contacting Sopheon's
registrar, Link Group on +44 (0)371 664 0321. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside the United
Kingdom will be charged at the applicable international rate. The helpline is
open between 9:00 a.m. to 5:30 p.m., Monday to Friday excluding public
holidays in England and Wales.  Please note that Link Group cannot provide
any financial, legal or tax advice and calls may be recorded and monitored for
security and training purposes.

For persons who receive a copy of this Announcement in electronic form or via
a website notification, a hard copy of this Announcement will not be sent
unless so requested. In accordance with Rule 30.3 of the Code, a person so
entitled may also request that all future documents, announcements and
information to be sent to them in relation to the Acquisition should be in
hard copy form.

Disclosure requirements of the Code

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of
any class of relevant securities of an offeree company or of any securities
exchange offeror (being any offeror other than an offeror in respect of which
it has been announced that its offer is, or is likely to be, solely in cash)
must make an Opening Position Disclosure following the commencement of the
offer period and, if later, following the announcement in which any securities
exchange offeror is first identified. An Opening Position Disclosure must
contain details of the person's interests and short positions in, and rights
to subscribe for, any relevant securities of each of (i) the offeree company
and (ii) any securities exchange offeror(s). An Opening Position Disclosure by
a person to whom Rule 8.3(a) applies must be made by no later than 3:30 p.m.
(London time) on the 10th business day following the commencement of the offer
period and, if appropriate, by no later than 3:30 p.m. (London time) on the
10th business day following the announcement in which any securities exchange
offeror is first identified. Relevant persons who deal in the relevant
securities of the offeree company or of a securities exchange offeror prior to
the deadline for making an Opening Position Disclosure must instead make a
Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1%
or more of any class of relevant securities of the offeree company or of any
securities exchange offeror must make a Dealing Disclosure if the person deals
in any relevant securities of the offeree company or of any securities
exchange offeror. A Dealing Disclosure must contain details of the dealing
concerned and of the person's interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) the offeree company and
(ii) any securities exchange offeror(s), save to the extent that these details
have previously been disclosed under Rule 8. A Dealing Disclosure by a person
to whom Rule 8.3(b) applies must be made by no later than 3:30 p.m. (London
time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding,
whether formal or informal, to acquire or control an interest in relevant
securities of an offeree company or a securities exchange offeror, they will
be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by
any offeror and Dealing Disclosures must also be made by the offeree company,
by any offeror and by any persons acting in concert with any of them (see
Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant
securities Opening Position Disclosures and Dealing Disclosures must be made
can be found in the Disclosure Table on the Takeover Panel's website at
www.thetakeoverpanel.org.uk, including details of the number of relevant
securities in issue, when the offer period commenced and when any offeror was
first identified. You should contact the Panel's Market Surveillance Unit on
+44 (0)20 7638 0129 if you are in any doubt as to whether you are required to
make an Opening Position Disclosure or a Dealing Disclosure.

 

Independent advice

 

If you are in any doubt about the contents of this Announcement or the action
you should take, you are recommended to seek your own independent financial
advice immediately from your stockbroker, bank manager, solicitor or
independent financial adviser duly authorised under FSMA if you are resident
in the United Kingdom or, if not, from another appropriately authorised
independent financial adviser.

 

 

 

 

 

 

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

All times shown are London times unless otherwise stated. All dates and times
are based on Sopheon's, Resurgens', Wellspring's and Bidco's current
expectations and are subject to change. If any of the dates and/or times in
this expected timetable change, the revised dates and/or times will be
notified to Sopheon Shareholders by announcement through a Regulatory
Information Service and by posting notice of these dates on the following
website: https://www.sopheon.com/investors.

 Event                                                                           Expected time and/or date
 Date of this document                                                           16 January 2024
 Latest time for lodging Forms of Proxy for:
 - Court Meeting (BLUE form)                                                     10:00 a.m. on 6 February 2024(( 1  (#_ftn1) ))
 - General Meeting (WHITE form)                                                  10:15 a.m. on 6 February 2024(( 2  (#_ftn2) ))
 Voting Record Time                                                              6:00 p.m. on 6 February 2024 (( 3  (#_ftn3) ))
 Court Meeting                                                                   10:00 a.m. on 8 February 2024
 General Meeting                                                                 10:15 a.m. on 8 February 2024(( 4  (#_ftn4) ))
 The following dates are indicative only and subject to change(( 5  (#_ftn5) ))
 (( 6  (#_ftn6) ))
 Court Hearing (to sanction the Scheme)                                          16 February 2024
 Last day of dealings in, and for registration of transfers of, and disablement  19 February 2024
 in CREST of, Sopheon Shares
 Scheme Record Time                                                              6:00 p.m. on 19 February 2024
 Dealings in Sopheon Shares on AIM suspended                                     7:30 a.m. on 20 February 2024
 Effective Date of the Scheme                                                    20 February 2024(( 7  (#_ftn7) ))
 Cancellation of admission to trading of Sopheon Shares                          at 7:00 a.m. on 21 February 2024
 Latest date for despatch of cheques and crediting of CREST stock accounts for   within 14 days after the Effective Date
 Acquisition consideration due under the Scheme
 Long Stop Date                                                                  4 March 2024(( 8  (#_ftn8) ))

 

The Court Meeting and the General Meeting will both be held at the offices of
Squire Patton Boggs (UK) LLP, 60 London Wall, London EC2M 5TQ on Thursday 8
February 2024.

 

 1  (#_ftnref1)      It is requested that BLUE Forms of Proxy for the
Court Meeting be lodged not later than 48 hours before the time appointed for
the Court Meeting, excluding any part of a day that is not a working day. BLUE
Forms of Proxy not so lodged may be handed to the Chair of the Court Meeting
or Link Group on behalf of the Chair of the Court Meeting before the start of
the Court Meeting.

 2  (#_ftnref2)     WHITE Forms of Proxy for the General Meeting must be
lodged not later than 48 hours before the time appointed for the General
Meeting, excluding any part of a day that is not a working day. WHITE Forms of
Proxy for the General Meeting not lodged by this time will be invalid. Please
see "Action to be taken" on page 11 of the Scheme Document.

 3  (#_ftnref3)     If either the Court Meeting or the General Meeting is
adjourned, the Voting Record Time for the relevant adjourned Meeting will be
the close of business on the day which is 48 hours (excluding any part of a
day that is not a working day) before the date of such adjourned Meeting.

 4  (#_ftnref4)     To commence at 10:15 a.m. (or as soon as reasonably
practicable thereafter as the Court Meeting shall have been concluded or
adjourned).

 5  (#_ftnref5)      These times and dates are indicative only and will
depend on, among other things, whether and when the Conditions are satisfied
or (where applicable) waived and the dates upon which the Court sanctions the
Scheme and a copy of the Court Order to sanction the Scheme is delivered to
the Registrar of Companies. If the expected date of the Court Hearing is
changed, Sopheon will give adequate notice of the changes by issuing an
announcement through a Regulatory Information Service and by posting notice of
these dates on the following website: https://www.sopheon.com/investors.

 6  (#_ftnref6)      Subject to the satisfaction of certain regulatory
conditions as set out in Part III (Conditions to and Further Terms of the
Scheme and the Acquisition) of the Scheme Document.

 7  (#_ftnref7)     This date will be the date on which a copy of the Court
Order is delivered to the Registrar of Companies.

 8  (#_ftnref8)     This is the latest date by which the Scheme may become
Effective unless Sopheon and Bidco agree, with the consent of the Panel and
(if required) the Court, a later date.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  SOAUNOBRSWUAAAR